SRPT Stock Risk & Deep Value Analysis
Sarepta Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About SRPT Stock
We analyzed Sarepta Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran SRPT through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
SRPT Risk Analysis & Red Flags
What Could Go Wrong
The primary risk is that the Q1 2026 profitability, significantly boosted by a one-time $365 million collaboration payment from Roche, may mask ongoing commercial execution challenges for Elevidys' underlying product volume. If sustainable product revenue growth for Elevidys does not materialize in subsequent quarters against the reaffirmed 2026 revenue guidance of $1.2B-$1.4B (down from $1.86B in 2025), investor confidence could erode, potentially leading to a sharp decline in stock price.
Risk Matrix
Overall
Moderate
Financial
Medium
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
High
Red Flags
- ⚠
Q1 2026 revenue declined -1.9% YoY, despite overall profitability, indicating challenges in core product sales growth.
- ⚠
Reaffirmed 2026 net product revenue guidance of $1.2B-$1.4B implies a significant contraction from 2025's $1.86B, signalling a slowdown in overall commercial growth.
- ⚠
Analyst commentary continues to reference Elevidys safety/regulatory concerns (patient deaths, serious adverse events), posing potential reputational and commercial risks.
- ⚠
High reliance on a single primary product (Elevidys) for future growth, making the company vulnerable to commercial or regulatory setbacks specific to this drug.
Upcoming Risk Events
- 📅
Escalation of Elevidys safety/regulatory concerns (Q2 2026 onwards): Any formal regulatory action (e.g., restricted use, black box warning) or significant increase in reported serious adverse events could severely impact Elevidys' commercial uptake and current revenue, potentially reducing annual sales by 20-50%.
- 📅
Failure or significant delay of the sNDA for traditional approval of PMO therapies (within 12 months): A rejection or prolonged delay would negate a key de-risking event for existing products, negatively impacting investor confidence and potential revenue growth for these assets.
- 📅
Q2 2026 revenue shortfall (Estimated early-August 2026): If Q2 product revenue (excluding collaboration) does not show significant sequential growth, it could indicate persistent commercial execution issues for Elevidys, leading to a negative market re-rating.
When to Reconsider
- 🚪
Exit if quarterly product revenue (excluding one-time collaboration revenues) shows continued sequential decline of >5% or fails to meet consensus estimates for two consecutive quarters.
- 🚪
Sell if the FDA issues any formal safety warning, restriction, or rejects the sNDA for traditional approval of existing PMO therapies, signalling a major regulatory setback.
- 🚪
Exit if 2026 revenue guidance is revised downwards again, specifically for product sales, or if non-GAAP operating margins fall below 15% for two consecutive quarters.
Unlock SRPT Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Sarepta Therapeutics Inc (SRPT) Do?
Market Cap
$1.89B
Sector
Healthcare
Industry
Biotechnology
Employees
1,372
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children's Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Visit Sarepta Therapeutics Inc WebsiteInvestment Thesis
If Sarepta can sustain the Q1 2026 profitability trend by demonstrating consistent quarter-over-quarter product revenue growth for Elevidys (excluding one-time collaboration revenue), alongside securing traditional FDA approval for its existing PMO therapies via the sNDA, then its current sub-2x 2026 P/S multiple could re-rate to 3-5x. This would imply a market cap of $3.9B-$6.5B, offering a 2-3x return from the current market cap, as the market assigns higher confidence to its commercial execution and pipeline value beyond initial launch challenges.
Is SRPT Stock Undervalued?
Unlock the full AI analysis for SRPT
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
SRPT Price Targets & Strategy
12-Month Target
$25.00
Bull Case
$37.00
Bear Case
$12.00
Valuation Basis
Based on 2.0x 2026 revenue guidance midpoint ($1.3B) on 105.7M shares outstanding.
Entry Strategy
Consider dollar-cost averaging around the current price of $17-$18.7 (support near 50-day SMA, if available). A dip towards $15-$16 could offer a more attractive entry, assuming fundamentals remain intact.
Exit Strategy
Take partial profits at $30-$35 as a first target. Place a stop-loss order if the stock breaks below $15-$16 (previous support levels) or if major negative news on Elevidys safety or regulatory status emerges.
Portfolio Allocation
5% for a moderate risk tolerance, acknowledging the inherent volatility and regulatory risks of a biotech company, balanced by its market leadership and recent profitability.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is SRPT Financially Healthy?
Valuation
P/E Ratio
29.00
Forward P/E
26.40
EV/EBITDA
31.70
PEG Ratio
-1.90
Price/Book
7.80
Price/Sales
6.10
Profitability
Gross Margin
70.45%
Operating Margin
-1.10%
Net Margin
2.98%
Return on Equity
4.89%
Revenue Growth
-2.20%
EPS
$0.07
Balance Sheet
Current Ratio
2.32
Quick Ratio
1.44
Debt/Equity
0.73
Total Debt
$1.04B
Cash & Equivalents
$748.00M
Cash Flow
Operating Cash Flow
$347.00M
Free Cash Flow
$216.00M
EBITDA
$412.00M
Other
Beta (Volatility)
0.20
Does SRPT Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
3 Identified
Sarepta's moat persists due to significant intellectual property protection, the high regulatory hurdles, and extensive development costs associated with bringing novel gene therapies to market. However, its durability is continuously tested by the need for ongoing innovation and successful commercialization against the backdrop of emerging competitors and potential safety concerns.
Moat Erosion Risks
- •Emergence of a competitor DMD gene therapy that demonstrates superior efficacy or a more favorable safety profile, eroding Elevidys' market share.
- •Any formal regulatory actions or more stringent safety requirements imposed on Elevidys or other key products by health authorities.
- •Expiry of key patents for its foundational technologies without successful new product launches to maintain its competitive edge.
SRPT Competitive Moat Analysis
Sign up to see competitive advantages
SRPT Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral. The EPS beat and return to profitability are positive, but the underlying product revenue challenges and existing safety concerns likely temper widespread retail enthusiasm.
Institutional Sentiment
Neutral. Previous analyst sentiment was largely negative with price targets below the current price. While the Q1 2026 results could begin to shift this, there's no widespread upgrade or strong institutional buying consensus in the provided data.
Insider Activity (Form 4)
No specific Form 4 insider buy or sell transactions were reported for the last 90 days. A Form 13F summary filed on May 13, 2026, had a $0 reported value and is not indicative of insider trading.
Options Flow
Normal options activity. No specific unusual options activity or put/call ratio direction was indicated in the provided research.
Earnings Intelligence
Next Earnings
Estimated early-August 2026 (for Q2 2026)
Surprise Probability
Medium
Historical Earnings Pattern
The stock reacted positively to the Q1 2026 earnings, which showed a significant swing to profitability and an EPS beat. Future reactions are likely to be strongly influenced by sustainable product revenue trajectory and any updates to full-year guidance.
Key Metrics to Watch
Competitive Position
Top Competitor
BMRN (BioMarin Pharmaceutical Inc.)
Market Share Trend
Stable to Gaining in the DMD gene therapy segment with its first-mover Elevidys, but facing ongoing commercialization challenges and the threat of emerging competition.
Valuation vs Peers
Potentially undervalued on P/S compared to peers with established rare disease portfolios, given its market leadership in DMD and recent swing to profitability, but trading at a premium on risk due to commercialization hurdles and regulatory scrutiny.
Competitive Advantages
- •First-mover advantage in the DMD gene therapy market with Elevidys.
- •Proprietary phosphorodiamidate morpholino oligomer (PMO) technology platform for RNA-targeted therapies.
- •Diversifying pipeline with promising assets in other genetic diseases (e.g., siRNA programs).
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive SRPT Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings Report (Estimated early-August 2026): Focus on sustainable Elevidys product volume growth (excluding one-time collaboration revenue) and continued non-GAAP profitability, to demonstrate consistent commercial traction beyond Q1's boost.
- •Continued commercial expansion of ELEVIDYS in Japan (Q2/Q3 2026): Successful market penetration and increasing product sales volumes in the Japanese market beyond the initial milestone payment, demonstrating global execution capabilities.
Medium-Term (6-18 months)
- •FDA decision on sNDA for traditional approval of PMO therapies (Exondys 51, Vyondys 53, Amondys 45) (Next 6-12 months): A positive decision would validate existing therapies, potentially improving market access, pricing flexibility, and significantly de-risking these revenue streams.
- •Progression of Phase 1/2 siRNA programs into later-stage clinical trials (e.g., Phase 3 initiation) (Next 9-18 months): Demonstrating pipeline progress beyond DMD would broaden Sarepta's therapeutic scope and future revenue streams, attracting new investor interest.
Long-Term (18+ months)
- •Global commercialization and market leadership for Elevidys in DMD (2027-2029): Achieving widespread adoption and maintaining market share for Elevidys globally could drive annual revenue beyond $3B+, positioning for multi-billion dollar market cap growth.
- •Successful development and commercialization of new gene therapies for additional rare diseases (2028-2030): Expanding the therapeutic pipeline beyond DMD could diversify revenue streams and establish Sarepta as a broader leader in genetic medicine, enabling a multi-bagger valuation.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for SRPT?
- ✓
Watch for quarterly Elevidys product revenue growth (excluding collaboration revenue) exceeding 5% sequentially, as a key indicator of improving commercial traction.
- ✓
Monitor the FDA's decision on the sNDA for PMO therapies for traditional approval; a positive outcome with favorable labeling would be a significant de-risking event.
- ✓
Observe if non-GAAP operating margin consistently stays above 20% in subsequent quarters, indicating sustained operational efficiency and profitability.
Bull Case Analysis
Sign up free to see the bull case
Competing with SRPT
See how Sarepta Therapeutics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Sarepta Therapeutics Inc SRPT | $1.9B | 6.8 | 29.0 | $730.8M | 3.0% | -2.2% | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Sarepta Therapeutics Inc Makes Money
Sarepta Therapeutics is a biopharmaceutical company specializing in the development and commercialization of precision genetic medicines, primarily focusing on rare diseases like Duchenne muscular dystrophy (DMD). The company generates revenue through the sale of its approved therapies, such as the gene therapy Elevidys and RNA-targeted exon-skipping drugs, to patients through healthcare providers. Additionally, they engage in strategic collaborations with other pharmaceutical companies, granting regional development and commercialization rights in exchange for upfront payments, milestones, and royalties. Their core strategy involves extensive research and development to bring innovative, often first-in-class, therapies through rigorous clinical trials and regulatory approval processes to address high unmet medical needs in niche patient populations.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Sarepta Therapeutics Inc (SRPT)?
As of June 1, 2026, Sarepta Therapeutics Inc has a DVR Score of 6.8 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Sarepta Therapeutics Inc?
Sarepta Therapeutics Inc's market capitalization is approximately $1.9B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Sarepta Therapeutics Inc use?
SRPT is the ticker symbol for Sarepta Therapeutics Inc. The company trades on the NMS.
What is the risk level for SRPT stock?
Our analysis rates Sarepta Therapeutics Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of SRPT?
Sarepta Therapeutics Inc currently has a price-to-earnings (P/E) ratio of 29.0. This is in line with broader market averages.
Is Sarepta Therapeutics Inc's revenue growing?
Sarepta Therapeutics Inc has reported revenue growth of -2.2%. Revenue has been declining, which warrants closer examination.
Is SRPT stock profitable?
Sarepta Therapeutics Inc has a profit margin of 3.0%. The company is profitable but margins are modest.
How often is the SRPT DVR analysis updated?
Our AI-powered analysis of Sarepta Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 1, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for SRPT (Sarepta Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.